Literature DB >> 9243315

Corticosteroid-induced central serous chorioretinopathy.

M Wakakura1, E Song, S Ishikawa.   

Abstract

Five patients were identified by medical records and fluorescein angiography as having developed central serous chorioretinopathy (CSC) during corticosteroid treatment. These five and 28 previously reported corticosteroid-induced CSC occurrences were studied to clarify the differences between idiopathic CSC and corticosteroid-induced CSC. Nine previously reported occurrences of corticosteroid-induced multiple posterior pigment epitheliopathy (MPPE) were also reviewed. Corticosteroid-induced CSC patients were older and less male-dominant; in MPPE, female patients predominated and most had bilateral involvement. The onset of CSC was within 70 days of corticosteroid administration in the short latency group, and more than 6 months after administration in the prolonged latency group. Daily doses of prednisolone usually exceeded 20 mg in the short latency group and was less than 20 mg in the prolonged latency group. Immunosuppressive agents such as cyclophosphamide were related to a lower daily dose at onset.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9243315     DOI: 10.1016/s0021-5155(97)00027-0

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  12 in total

1.  Severe visual loss in a breast cancer patient on chemotherapy.

Authors:  Joan Giralt; Amanda Rey; Rafael Villanueva; Socorro Alforja; Ricardo P Casaroli-Marano
Journal:  Med Oncol       Date:  2012-02-22       Impact factor: 3.064

2.  Severe visual loss secondary to central serous chorioretinopathy following prolonged immune suppression with oral prednisolone.

Authors:  A Harikrishnan; K Anderson; S Patra
Journal:  JRSM Short Rep       Date:  2010-09-15

3.  Circadian disturbance and idiopathic central serous chorioretinopathy.

Authors:  Elodie Setrouk; Beatrice Hubault; Frédérique Vankemmel; Olivia Zambrowski; Pierre Nazeyrollas; Brigitte Delemer; Vincent Durlach; Alain Ducasse; Carl Arndt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-05-21       Impact factor: 3.117

4.  Glucocorticoid use represents a risk factor for central serous chorioretinopathy: a prospective, case-control study.

Authors:  Panagiotis Karadimas; Evrydiki A Bouzas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-09       Impact factor: 3.117

Review 5.  [Central serous chorioretinopathy].

Authors:  Laurenz Pauleikhoff; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmologe       Date:  2021-04-16       Impact factor: 1.059

6.  Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study.

Authors:  Der-Chong Tsai; Shih-Jen Chen; Chin-Chou Huang; Pesus Chou; Chia-Min Chung; Po-Hsun Huang; Shing-Jong Lin; Jaw-Wen Chen; Tseng-Ji Chen; Hsin-Bang Leu; Wan-Leong Chan
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

7.  Forgotten exogenous corticosteroid as a cause of central serous chorioretinopathy.

Authors:  Paul W Hardwig; Amila O Silva; Jose S Pulido
Journal:  Clin Ophthalmol       Date:  2008-03

8.  Central serous chorioretinopathy with and without steroids: A multicenter survey.

Authors:  Takashi Araki; Hiroto Ishikawa; Chiharu Iwahashi; Masanori Niki; Yoshinori Mitamura; Masahiko Sugimoto; Mineo Kondo; Takamasa Kinoshita; Tomo Nishi; Tetsuo Ueda; Aki Kato; Tsutomu Yasukawa; Yoshihiro Takamura; Fumi Gomi
Journal:  PLoS One       Date:  2019-02-28       Impact factor: 3.240

9.  Retinal and choroidal changes in steroid-associated central serous chorioretinopathy.

Authors:  Vikas Ambiya; Abhilash Goud; Mohammed Abdul Rasheed; Sankeert Gangakhedkar; Kiran Kumar Vupparaboina; Jay Chhablani
Journal:  Int J Retina Vitreous       Date:  2018-04-02

10.  Cushing's Syndrome and Hypothalamic-Pituitary-Adrenal Axis Hyperactivity in Chronic Central Serous Chorioretinopathy.

Authors:  Femke M van Haalen; Elon H C van Dijk; Olaf M Dekkers; Maurice B Bizino; Greet Dijkman; Nienke R Biermasz; Camiel J F Boon; Alberto M Pereira
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-20       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.